中国头部创新药企，进入价值释放加速期。近日，备受市场瞩目的核药龙头远大医药（http://0512.HK）公布了中期财报。2025年上半年，公司上半年取得了多项重磅创新突破，经营业绩保持稳健增长，实现了营业收入的新高约61.1亿港元，其中创新壁垒产品收入占比约51%，同比提升约15个百分点，公司净利润约11.7亿港元。上半年，随着远大医药一系列创新和壁垒产品实现快速放量，公司集采影响已出清，展现出...
Source Link中国头部创新药企，进入价值释放加速期。近日，备受市场瞩目的核药龙头远大医药（http://0512.HK）公布了中期财报。2025年上半年，公司上半年取得了多项重磅创新突破，经营业绩保持稳健增长，实现了营业收入的新高约61.1亿港元，其中创新壁垒产品收入占比约51%，同比提升约15个百分点，公司净利润约11.7亿港元。上半年，随着远大医药一系列创新和壁垒产品实现快速放量，公司集采影响已出清，展现出...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.